Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 41.58B |
| Revenue (ttm) | 28.16B |
| Net Income (ttm) | 951.57M |
| Shares Out | 3.14B |
| EPS (ttm) | 0.29 |
| PE Ratio | 45.69 |
| Forward PE | 23.04 |
| Dividend | $0.62 (4.68%) |
| Ex-Dividend Date | Mar 27, 2024 |
| Volume | 1,948,745 |
| Open | 13.21 |
| Previous Close | 13.37 |
| Day's Range | 13.17 - 13.30 |
| 52-Week Range | 12.77 - 16.58 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 20.00 (+50.94%) |
| Earnings Date | May 9, 2024 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, ... [Read more]
Full Company ProfileFinancial Performance
In 2023, TAK's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.
Financial numbers in JPY Financial StatementsAnalyst Forecast
According to one analyst, the rating for TAK stock is "Buy" and the 12-month stock price forecast is $20.0.
News
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results
Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of si...
Takeda Projects Lower Annual Profit After Quarterly Loss
The Japanese drugmaker reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses.
Japan's Takeda Pharma says full-year profit slumps 56%
Japan's Takeda Pharmaceutical said full-year earnings slumped by 56% as the company focused on rebuilding its drug pipeline to make up for the loss of patent protection for major sellers.
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating ...
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recomm...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statisti...
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: N...
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) admi...
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to i...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Takeda's 'In Their Shoes' initiative illuminates the daily struggles of IBD patients in the UAE, fostering empathy and understanding among participants. DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Take...
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors ...
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa ...
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) ...
Advanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]
DALLAS--(BUSINESS WIRE)--AIC, a division of AIS Healthcare, now offers GLASSIA and ARALAST NP, manufactured by Takeda, for the treatment of adult patients with clinically evident emphysema due to seve...
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the ...
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production
Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
CAMBRIDGE, Mass. & HYDERABAD, India--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic ...
US FDA approves Takeda's therapy for allergic inflammation in esophagus
Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the conditio...
FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the fir...
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024.
Takeda Announces Chief Financial Officer Succession
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country o...
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-t...
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigatio...
Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. Food and Drug Administration (FDA) approves GAMMAGARD LIQUID for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that the EC approved HYQVIA as maintenance therapy in patients of all ages with CIDP after stabilization with IVIG.